Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Additionally we are shipping ATXN7 Kits (4) and and many more products for this protein.
Showing 10 out of 50 products:
Human Monoclonal ATXN7 Primary Antibody for ICC, IF - ABIN2668230
Yvert, Lindenberg, Picaud, Landwehrmeyer, Sahel, Mandel: Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice. in Human molecular genetics 2000
Show all 2 references for ABIN2668230
Chicken Polyclonal ATXN7 Primary Antibody for WB - ABIN2777891
Mu, Lin, Chen, Sung, Bai, Jow: The perinatal outcomes of asymptomatic isolated single umbilical artery in full-term neonates. in Pediatrics and neonatology 2009
Show all 2 references for ABIN2777891
South American cohort did not confirm the effect of the four candidate loci as modifier of onset age: mithocondrial A10398G polymorphism and CAGn at RAI1 (show DOM3Z Antibodies), CACNA1A (show CACNA1A Antibodies), ATXN3 (show ATXN3 Antibodies), and ATXN7 genes
Our study provided the clinico-genetic analysis of nine Indian SCA7 families and CAG repeat (show CELF3 Antibodies) distribution analysis in diverse Indian populations showed occurrence of ATXN7-CAG intermediate alleles in a predisposed population
Data show that the aggregates formed by polyQ-expanded ataxin 7 sequester ubiquitin-specific protease (USP22 (show USP22 Antibodies)) through specific interactions.
Two pathological polyglutamine proteins, truncated Ataxin-7 and full-length Ataxin-3 (show ATXN3 Antibodies), suggest that accumulation of insoluble aggregates beyond a critical threshold could be responsible for neurotoxicity.
The proband exhibited a typical phenotype of SCA7, which includes cone dystrophy and spinocerebellar ataxia (show USP14 Antibodies).
Results suggest that sequestration of both enzymatic centers in SAGA upon ATXN7 poly(Q) expansion likely contributes to spinocerebellar ataxia (show USP14 Antibodies) type 7 development and progression.
This study shown evidence in vivo, in the SCA7 KI mouse model, that progressive accumulation of mutant ataxin-7 impairs autophagy.
Epidemiological evidence of a SCA7 founder effect in a Mexican population with spinocerebellar ataxia (show USP14 Antibodies).
analysis of the founder effect and ancestral origin of the spinocerebellar ataxia (show USP14 Antibodies) type 7 mutation in Mexican families
Haplotype and phylogenetic analyses provide evidence showing that the relatively high frequency of SCA7 in Mexican population is the result of a founder mutation and that Mexican SCA7 carriers possess the Western European ancestry.
Spleen-specific isoform of Pax5 (show PAX5 Antibodies) and Ataxin-7 can be considered as spleen-specific unique molecular markers for the evaluation of splenomegaly and lympho-proliferative disorders.
we found that HDAC3 (show HDAC3 Antibodies) increased the posttranslational modification of normal and expanded ataxin-7.
These results demonstrate that suppression of mutant ataxin-7 expression by only 50% in a polyQ disease model can have a significant impact on disease phenotypes, even when initiated after the onset of detectable behavioral deficits
findings demonstrate that loss of Gcn5 (show KAT2A Antibodies) functions can contribute to the time of onset and severity of SCA7 phenotypes, and suggest that non-transcriptional functions of SAGA may play a role in neurodegeneration in this disease
Ataxin-7 gene expression is governed by an antisense ncRNA transcript, SCAANT1, within the ataxin-7 repeat region where the CTCF (show CTCF Antibodies) binding sites reside, which regulates a previously unrecognized ataxin-7 sense promoter by convergent transcription.
polyglutamine-expanded ataxin-7 upregulates the expression of Bax (show BAX Antibodies) and Puma (show BBC3 Antibodies) and causes apoptotic neuronal death by enhancing phosphorylation and transcriptional activity of p53 (show TP53 Antibodies).
study suggests that polyglutamine-expanded ataxin-7-induced transcriptional dysregulation causes cerebellar dysfunction and ataxia (show USP14 Antibodies)
These results demonstrate an influence of SUMOylation on the multistep aggregation process of ATXN7 and implicate a role for ATXN7 SUMOylation in SCA7 pathogenesis.
glutamine expansion stabilizes mutant ataxin-7, provide an explanation for selective neuronal vulnerability, and show that mutant ataxin-7 impairs posttetanic potentiation (PTP).
The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the 'pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. This locus has been mapped to chromosome 3, and it has been determined that the diseased allele associated with spinocerebellar ataxia-7 contains 38-130 CAG repeats (near the N-terminus), compared to 7-17 in the normal allele. The encoded protein is a component of the SPT3/TAF9/GCN5 acetyltransferase (STAGA) and TBP-free TAF-containing (TFTC) chromatin remodeling complexes, and it thus plays a role in transcriptional regulation. Alternative splicing results in multiple transcript variants.
, spinocerebellar ataxia type 7 protein
, spinocerebellar ataxia 7 homolog
, spinocerebellar ataxia type 7 protein homolog